Type
Bhwana D, Siewe Fodjo JN, Amaral L-J, Vandevenne L, Francis F, Challe DP, et al. Disability assessment among persons with epilepsy in Mahenge, an onchocerciasis-endemic area in Tanzania: A cross-sectional study. Epilepsy & Behavior. 2023;146:109367.
View
Type
Guidelines
View
Type
Jada SR, Amaral L-J, Lakwo T, Carter JY, Rovarini J, Bol YY, et al. Effect of onchocerciasis elimination measures on the incidence of epilepsy in Maridi, South Sudan: a 3-year longitudinal, prospective, population-based study. The Lancet Global Health [Internet]. 2023;11(8):e1260-e1268. Available from: https://www.thelancet.com/action/showPdf?pii=S2214-109X%2823%2900248-6
View
Type
Boakye D, Mackenzie C, Tallant J, Heggen A, Leff S, Nadjilar L, et al. Enhancing onchocerciasis elimination program management: A biological approach to deciding when to begin Stop Mass Drug Administration activities. Basáñez M-G. PLOS Neglected Tropical Diseases [Internet]. 2023;17(7):1-8. Available from: https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0011348&type=printable
View
Type
Siewe Fodjo JN, Van Cutsem G, Amaral L-J, Colebunders R. Mortality among persons with epilepsy in onchocerciasis-endemic and non-endemic areas of sub-Saharan Africa: A systematic review and meta-analysis. Seizure: European Journal of Epilepsy [Internet]. 2023;110:253-261. Available from: https://www.sciencedirect.com/science/article/pii/S1059131123001899/pdfft?md5=64d3f32106b48902bf817f49ea150b5f&pid=1-s2.0-S1059131123001899-main.pdf
View
Type
Surakat OA, Sam-Wobo SO, Golden A, De Los Santos T, Adeleke MA, Faulx D, et al. Field test and sensitivity of Onchocerciasis rapid test in Ogun State, Nigeria. Research Journal of Health Sciences [Internet]. 2023;11(3):213-223. Available from: https://www.ajol.info/index.php/rejhs/article/view/249942/236304
View
Type
Adamou S, Boakye D, Bouckari L, Heggen A, Tallant J, Youssouf Y, et al. Successful completion of onchocerciasis elimination mapping (OEM) in Niger, West Africa. International Health [Internet]. 2023;:1-3. Available from: https://academic.oup.com/inthealth/advance-article-pdf/doi/10.1093/inthealth/ihad032/50321496/ihad032.pdf
View
Type
McPherson S, Tafese G, Tafese T, Behaksra SW, Solomon H, Oljira B, et al. Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia. EClinicalMedicine [Internet]. 2023;59:101984. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154979/pdf/main.pdf
View
Type
Zoerhoff KL, Mbabazi PS, Gass K, Kraemer J, Fuller BB, Blair L, et al. How well do coverage surveys and programmatically reported mass drug administration coverage match? Results from 214 mass drug administration campaigns in 15 countries, 2008-2017. BMJ global health [Internet]. 2023;8(5):1-14. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163531/pdf/bmjgh-2022-011193.pdf
View
Type
Enyama D, Koum D-CK, Tounde BT, Njinkui DN, Mapoure YN. Challenges in the Management of Childhood Epilepsy in a Rural Area with Endemic Onchocerciasis in Cameroon. Pediatric Oncall [Internet]. 2023;21(2). Available from: https://www.pediatriconcall.com/pediatric-journal/view/fulltext-articles/1464/J/0/0/802/0
View